Evomela
HER2 Negative Breast Carcinoma
General Oncology, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the HER2 Negative Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palazestrant Olema Pharmaceuticals, Inc. | Phase 3 | BB |
c105 University of Washington | Phase 2 | B |
Yb-1 University of Washington | Phase 2 | B |
SRY-BOX TRANSCRIPTION FACTOR 2 University of Washington | Phase 2 | B |
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine University of Washington | Phase 2 | B |
FILGRASTIM General Oncology, Inc. | Phase 1 | CC |
CARMUSTINE General Oncology, Inc. | Phase 1 | CC |
Same molecule, other indications
Evomela is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →